Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Liabilities and Shareholders Equity (2020 - 2023)

Historic Liabilities and Shareholders Equity for Candel Therapeutics (CADL) over the last 4 years, with Q3 2023 value amounting to $50.1 million.

  • Candel Therapeutics' Liabilities and Shareholders Equity fell 4110.96% to $50.1 million in Q3 2023 from the same period last year, while for Dec 2023 it was $176.0 million, marking a year-over-year decrease of 5077.57%. This contributed to the annual value of $77.7 million for FY2022, which is 1290.73% down from last year.
  • Per Candel Therapeutics' latest filing, its Liabilities and Shareholders Equity stood at $50.1 million for Q3 2023, which was down 4110.96% from $58.7 million recorded in Q2 2023.
  • In the past 5 years, Candel Therapeutics' Liabilities and Shareholders Equity ranged from a high of $101.6 million in Q1 2022 and a low of $30.7 million during Q2 2021
  • In the last 4 years, Candel Therapeutics' Liabilities and Shareholders Equity had a median value of $77.7 million in 2022 and averaged $71.6 million.
  • In the last 5 years, Candel Therapeutics' Liabilities and Shareholders Equity skyrocketed by 20347.71% in 2022 and then crashed by 4110.96% in 2023.
  • Over the past 4 years, Candel Therapeutics' Liabilities and Shareholders Equity (Quarter) stood at $38.3 million in 2020, then skyrocketed by 133.02% to $89.2 million in 2021, then decreased by 12.91% to $77.7 million in 2022, then crashed by 35.56% to $50.1 million in 2023.
  • Its Liabilities and Shareholders Equity was $50.1 million in Q3 2023, compared to $58.7 million in Q2 2023 and $67.2 million in Q1 2023.